Evaluation of external radiation exposure rate from radioiodine-treated hyperthyroid patients and radiation safety considerations

Nuclear Medicine Communications

Volumn 17, Issue 8, 1996, Pages 692-695

  Demir, M ^a   Kabasakal, Levent ^a   Onsel C ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HYPERTHYROIDISM; MALE; RADIATION EXPOSURE; RADIATION PROTECTION; RADIOISOTOPE THERAPY;

EID: 0029781565     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1080/00006231-199608000-00008     Document Type: Article

References (14)

1. Clarke SEM. Radioiodine therapy of the thyroid. In: Murray IPC, Ell PJ, Strauss HW, eds. Nuclear medicine in clinical diagnosis and treatment. Edinburgh: Churchill Livingstone, 1994: 833-845.
2. Beirwaltes WH, Widman J. How harmful to others are iodine-131 treated patients. J Nucl Med 33: 2116-2117.
3. Culver CM, Dworkin HJ. Radiation safety considerations for post-I-131 hyperthyroid therapy. J Nucl Med 1992; 33: 169-173.
4. McCready VR. A different approach to the use of unsealed radionuclides for cancer therapy. Eur J Nucl Med 1995; 22: 1-3.
5. Stabin MG, Watson EE, Marcus CS, Salk RD. Radiation dosimetry for the female and foetus from iodine-131 administration in hyperthyroidism. J Nucl Med 1991; 32: 808-813.
6. ICRP. Recommendations of the International Commission on Radiological Protection: ICRP-60. Oxford: Pergamon Press, 1990.
7. National Council on Radiation Protection and Measurements. Precautions in the management of patients who have received therapeutic amounts of radionuclides: NCRP-37. Washington, DC: NCRP, 1970.
8. National Council on Radiation Protection and Measurements. Protection in nuclear medicine and ultrasound diagnostic procedures in children: NCRP-73. Washington, DC: NCRP, 1983.
9. Williemsen UF, Knesewitsch P, Kreisig T, Pickardt CR, Kirsch CM. Functional results of radioiodine therapy with a 300-Gy absorbed dose in Graves’ disease. Eur J Nucl Med 1993; 20: 1051-1055.
10. Nuclear Regulatory Commission. Regulatory analysis on criteria for the release of patients administered radioactive material. Washington, DC: NRC, 1994.
11. Hall ET. The hidden dimension. New York: Doubleday, 1966: 117-121.
12. Becker DV, Siegel BA. Guidelines for patients receiving radioiodine treatment. New York: Society of Nuclear Medicine, 1983.
13. Nishizawa K, Ohara K, Oshima M, Maekoshi H, Orioto T, Watanabe T. Monitoring of 1-131 excretions and used materials of patients treated with 1-131. Health Phys 1980; 3: 467-481.
14. Rommey BM, Nickoloff EL. Diagnostic nuclear medicine and nursing mothers. Appl Radiol 1987; 5: 51-56.